Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Novocure (NVCR) Tops Q2 EPS by 6c, Revenues Beat
July 25, 2019 6:16 AM EDTNovocure (NASDAQ: NVCR) reported Q2 EPS of ($0.01), $0.06 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $86.7 million versus the consensus estimate of $80.24 million.
Quarterly net revenues of $86.7 million, representing 41 percent growth versus the second quarter 2018The NovoTTF-100L System FDA approved to treat malignant pleural mesothelioma in combination with standard chemotherapies, Novocures first FDA-approved torso... More